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Nicotine use is very prevalent in the schizophrenic population, which is a 2.5 fold greater than 
the general population. In the present study, the drug quinpirole (dopamine D2/D3 agonist) or 
saline was given neonatally to 25 Sprague-Dawley male and female rats. Rats were randomly 
assigned to condition. Beginning postnatal day 33 animals were given twice daily 
administrations of nicotine (0.5 mg/kg free base). After the first of the daily injections they were 
placed in a locomotor arena every other day for behavioral testing. One day after behavioral 
testing, the dorsal striatum and nucleus accumbens were removed for brain-derived neurotrophic 
factor (BDNF) assay. BDNF is a neurotrophin that plays an important role in neuronal 
development, neuronal maintenance and plasticity, and synaptic activity. Results showed that 
nicotine produced locomotor sensitization but this was not enhanced by neonatal quinpirole, 
unlike past work. Regarding BDNF, there was a significant increase in the nucleus accumbens in 
rats treated with nicotine; neonatal quinpirole increased the BDNF response produced by 
nicotine. Nicotine produced an increase in dorsal striatum BDNF that was not affected by 
neonatal quinpirole treatment. Importantly, it appears that nicotine administrations, that occurred 
in two different contexts, may result in differential behavioral results relative to nicotine 
administrations given consistently in the same context. 
  
Introduction 
Schizophrenia is a mental disorder that can be severely debilitating. It affects as much as 
1% of the population and is a common disorder seen in institutions today (Asher & Gask, 2010). 
As stated in the DSM-IV TR, to be clinically diagnosed with schizophrenia, one must have at 
least two of the following symptoms for at least one month: delusions, hallucinations, 
disorganized speech, grossly disorganized or catatonic behavior, and negative symptoms 
(American Psychiatric Association, 2000).  
Negative symptoms in schizophrenia are defined as “weakening or lack of normal 
thoughts, emotions or behavior” (Makinen, Miettunen, Isohanni, & Koponen, 2008, p. 334). One 
in three people diagnosed with schizophrenia has negative symptoms (Makinen et al., p. 334). 
Positive symptoms include delusions, hallucinations, thought disorders, and movement disorders. 
These symptoms prevent the person from functioning as they do normally. They put stress on 
relationships with family and friends, their occupations, academics, etc. These must last for a six 
month period with at least one month of the previously mentioned symptoms.  
A common problem observed in schizophrenic patients is substance abuse. Ringen et al. 
(as cited in Asher & Gask, 2010, p. 1) reported that “11.9% of the people with schizophrenia 
comorbid drug abuse or dependence.” There are many theories on why this is so. Drugs that are 
commonly abused are nicotine, alcohol, and cannabis. By studying substance abuse in 
schizophrenic patients, which has devastating health consequences, methods can be formed to 
prevent them from dying at such an early age (Kotov, Guey, Bromet, &Schwartz, 2010). 
 In a study completed by Leon and Diaz (as cited in Kotov et al., 2010) they estimated 
that 62% of the schizophrenic population smokes.  This raised the question by Kotov, Guey, 
Bromet, and Schwartz (2010), whether there was a correlation between schizophrenia and 
smoking. They took a sample size of 542 patients and followed them for 10 years after their first 
hospitalization. The authors also completed 5 interviews with the patient. The average number of 
cigarettes smoked per day was 16.1.  The findings showed a 2.5 fold greater use than the U.S. 
population. Smoking increased during periods of depression (Kotov et al., 2010). Many studies 
have been conducted in order to better understand the correlation of nicotine abuse in the 
schizophrenic population. 
Previously in the lab, we have shown that neonatal treatment with the dopamine D2/D3 
agonist quinpirole results in long-term increases in dopamine D2 receptor sensitivity, a 
phenomenon known as ‘D2 Priming. Neonatal quinpirole treatment also produces several 
different abnormal behaviors and cognitive impairments similar to schizophrenia (Brown, Perna, 
Schaefer, & Williams, 2006). Neonatal quinpirole also results in decreased neurotrophins in the 
hippocampus and frontal cortex, such as BDNF, which may play a role in long term cognitive 
effects due to increased activity at the D2 receptor (Brown, Flanigan, Thompson, Thacker, 
Schaefer, & Williams, 2004). 
Brain-derived neurotrophic factor (BDNF) is a neurotrophin that plays an important role 
in neuronal development, neuronal maintenance and plasticity, and synaptic activity (Brown et 
al., 2006). It is the most widely distributed neurotrophic factor found in the central nervous 
system. BDNF is found in the hippocampus and prefrontal cortex, which are areas in the brain 
that mainly function in cognitive performance (Brown et al., 2006). Several studies have shown 
that nicotine produces an increase in neurotrophins in several different brain areas (Kenny et al., 
2000; French, et al., 1999).Multiple research studies have linked a correlation in involvement of 
BDNF in the pathophysiology of schizophrenia. Positive and Negative Syndrome Scale 
(PANSS) symptoms have been shown to lower in schizophrenics who smoked compared to 
schizophrenics who did not smoke and BDNF levels were higher in the smokers than in the 
nonsmokers (Zhang, Xiu, Chen, Yang, Wu, Lu, Kosten, & Kosten, 2010).  It has been suggested 
that this change may be associated with nicotine receptor-induced upregulation of BDNF (Zhang 
et al., 2010). Based on these findings, schizophrenics have decreased BDNF levels compared to 
the general population. Nicotine increases these BDNF levels. It is hypothesized that there will 
be an increase in BDNF in the rats that are administered nicotine. 
Materials and Methods 
A total of 25 Sprague-Dawley rats were raised in our animal colony. These animals were 
the offspring of 5 pregnant females acquired from Harlan, Inc. (Indianapolis, IN). A total of 14 
females and 11 males were used as subjects in this study. There were categorized into 4 groups 
depending on neonatal drug (Quinpirole = Q; Saline = S) and adolescent drug (Nicotine = N; 
Saline = S) treatment: SN= 7, SS= 6, QN= 6, and QS=6.  The day of birth is referred to as 
postnatal day (P) zero or P0. Rats were injected with quinpirole (1mg/kg) or saline, 
intraperitoneally, on P1 through P21, through random assignment. P21 marked when they were 
weaned from the female dam and were raised to P29. The subjects were then housed 2-4 rats per 
cage. The adolescent rats lived in a room that was climate-controlled with a 12 hour light-dark 
cycle.  
At P29 the rats were habituated to the locomotor arena. Habituation is used so that the 
rats get repeated exposure to the injections and locomotor arena so that the behavioral responses 
are not due to sensory adaptation or motor fatigue. They were injected with saline from P29 to 
P31, and then placed in the locomotor arena for 10 minutes, 10 minutes post injection. Nicotine 
sensitization began at P33 and ended at P49. The subjects were injected twice daily with saline 
or nicotine (0.5 mg/kg), i.p. in the morning and afternoon on each day. This represents a dose 
that was 4 times what we had previously administered to adolescent rats.  They were tested every 
other day in the locomotor arena for a total of 9 days. Rats were placed in the locomotor arena 
ten minutes after they were injected i.p. with either nicotine or saline. The locomotor arena 
consisted of four wooden boxes placed next to each other that were painted flat black. They 
measured 40 cm on each side. One rat was placed in each box so that four rats could be recorded 
at a time. A digital camera was placed above the locomotor arena, which was connected to Any 
Maze (Stoelting, Wood Dale, IL) tracking system software. This software measured behavior by 
keeping track of horizontal activity. The software program places a digital grid with 5 cm x 5cm 
squares. Each time the subject crosses the line it counts as horizontal activity.  
The brain tissue was taken on P50 to be analyzed for BDNF levels. The brain areas that 
were dissected were the dorsal striatum and the nucleus accumbens. These specific areas are 
where dopaminergic pathways run and where decrease levels of BDNF occur in individuals with 
schizophrenia. In the accumbal area, nicotine is known to increase levels of BDNF (Correll et al., 
2009). These brain areas were also studied because neonatal quinpirole treatment results in a 
significant decrease in G-protein signaling (RGS), specifically Rgs9, in the striatum, nucleus 
accumbens, and frontal cortex (Maple, Perna, Parlaman, Stanwood, & Brown, 2007).  This 
decrease in RGS is similar to findings observed in postmortem samples of striatum in 




A 2 x 2 x 2 ANOVA was used for statistical analysis. Activity counts are presented as a 
function of day in Figure 1 A 2 (neonatal drug treatment) x 2 (adolescent drug treatment ) x 2 
(day of testing) revealed a significant main effect of adolescent drug treatment F(1,20) = 9.74, 
p<.005, day of testing F(1,20)=128.28, p<.001 and a significant two-way interaction of 
adolescent drug treatment x day of testing F(1,20)= 41.10, p<.001. Nicotine produced an 
increase in locomotor activity on day 9, but there were no effects on day 1. Importantly, neonatal 
quinpirole did not enhance sensitization to nicotine at day 9. 
BDNF is presented as a function of drug group in Figure 2 for dorsal striatum (left 
column) and nucleus accumbens (right right column).  For the striatum, a 2 (neonatal drug 
treatment) x 2 (adolescent drug treatment) x 2 (day of testing) revealed a significant main effect 
of adolescent drug treatment F(1,20) = 5.41, p<.032. Nicotine produced an increase in striatal 
BDNF that was not affected by neonatal quinpirole treatment. 
For the nucleus accumbens, a 2 (neonatal drug treatment) x 2 (adolescent drug treatment) 
x 2 (day of testing) revealed a significant main effect of neonatal F(1,20) = 13.15, p<.002 and 
adolescent drug treatment F(1,20) = 16.65, p<.001. Both neonatal quinpirole and adolescent 
nicotine produced a significant increase of BDNF in the nucleus accumbens. An independent t-
test revealed a significant increase in Group QN as compared to Group SN (p<.001). Therefore, 
it appears neonatal quinpirole increased the BDNF response produced by nicotine. 
Discussion 
Findings revealed that the behavioral data of locomotor sensitization showed there was 
no effect on day 1, but nicotine did produce an increase in activity on day 9. The results on figure 
1 show that neonatal quinpirole did not enhance nicotine sensitization at day 9. This may be due 
to the fact that nicotine was administered once every other day in the locomotor arena, but was 
administered at their cage the other 3 times. Since adolescents were receiving the drug’s 
rewarding effects at their cage more often than the locomotor arena, this may have resulted in a 
reduced behavior effect of nicotine in rats neonatally treated with quinpirole. Studies have shown 
that nicotine is known to have strong associations with non-reinforcing cues (Palmatier, O’Brien, 
& Hall, 2011). Based on these data, this would suggest that nicotine’s association with non-
reinforcing cues may alter the behavioral effects in neonatal quinpirole treated animals, yet not 
block sensitization altogether. Neurochemical findings showed that nicotine altered BDNF levels 
in quinpirole treated rats. In the nucleus accumbens, there was an increased BDNF response in 
the QN group when compared to the SN group. This is consistent with previous findings in this 
laboratory (Correll, Noel, Sheppard, Thompson, Li, Yin, & Brown, 2009).  However, BDNF 
levels were not affected by neonatal quinpirole treatment when looking at the dorsal striatum 
results. By analyzing figure 2, the nicotine did produce an increase in BDNF, but it was not 
related to neonatal quinpirole. 
As mentioned previously, schizophrenic individuals have decreased BDNF levels. 
Nicotine increases BDNF levels, which decreases some of the abnormal behavioral effects 
brought on by this disorder. In a study completed by Tizabi, Copelland, Brus, & Kostrzewa 
(1999), it was observed that nicotine is able to block some of the behavior effects caused by 
quinpirole. This is directly related to the nicotinic receptor antagonist, mecamylamine, in which 
there is an increase of receptor binding. These results suggest that nicotinic agonists may shine 
light in possible therapeutic agents for disorders related to the dopamine system (Tizabi et al., 
1999).  However, with increased BDNF levels observed in regions of the brain due to nicotine 
treatment, it suggests that nicotine is involved in changes in neural development and 
maintenance. With much change observed in adolescent brain development, there could be 
serious consequences. The increased amount of smoking seen in the schizophrenic population is 
a health hazard and is causing premature deaths. It is important to try and break the habit of 
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